



# Clinical Practice Guidelines for Liver Cancer

**2017 Version**

JSH HCC Guidelines 2017

Compiled by the Japan Society of Hepatology



KANEHARA & Co., LTD.

**List of Clinical Questions and Recommendations in the Clinical Practice Guidelines for Liver Cancer**

**Background to the Guidelines**

**Chapter 1: Surveillance and Diagnosis**

**Chapter 2: Treatment Algorithm**

**Chapter 3: Prevention**

**Chapter 4: Surgery**

**Chapter 5: Percutaneous Ablation**

**Chapter 6: Transcatheter Arterial Chemoembolization and Transcatheter Arterial Embolization**

**Chapter 7: Drug Therapy**

**Chapter 8: Radiation Therapy**

**Chapter 9: Post-treatment Surveillance and Prevention and Treatment of Recurrent HCC**

## ● General Affairs Committee of the Clinical Practice Guidelines for Liver Cancer

### Committee Chair

Satoshi Mochida (Director and Chair of the Planning and Public Relations Committee), Professor, Department of Gastroenterology and Hepatology, Saitama Medical Center, Saitama Medical University

### Committee Members

Kazuhiko Koike (Director), Professor, Department of Gastroenterology, The University of Tokyo

Masayoshi Kage (Board Member), Professor of the Research Center for Innovative Cancer Therapy, Kurume University

Shigeki Arii (Special Revision Committee Member for the third edition and Honorary Member), Hospital Director, Hamamatsu Rosai Hospital

Takafumi Ishida (Honorary Revision Committee Member for the third edition), Hospital Director, Shonan Tobu General Hospital

Masatoshi Makuuchi (the first and second editions; Chair and honorary member), Hospital Director, Towa Hospital

Keiji Sano (External Review Panel Chair for the third edition), Professor, Department of Surgery, Teikyo University School of Medicine

## ● Revision Committee of the Clinical Practice Guidelines for Liver Cancer

### Committee Chair

Norihiro Kokudo, President, National Center for Global Health and Medicine

### Vice Chair

Tadatoshi Takayama, Professor, Division of Digestive Surgery, Nihon University School of Medicine

### Assistant Committee Chair

Kiyoshi Hasegawa, Associate Professor, Hepato-Biliary-Pancreatic Surgery Division and Artificial Organ and Transplantation Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo

### Committee Members

### Surgeons

Shoji Kubo, Professor, Department of Hepato-Biliary-Pancreatic Surgery, Osaka City University Graduate School of Medicine

Mitsuo Shimada, Professor, Department of Surgery, Tokushima University Graduate School of Medicine

Hiroaki Nagano, Professor, Department of Gastroenterological, Breast, and Endocrine Surgery, Yamaguchi University Graduate School of Medicine

Etsuo Hatano, Professor, Department of Hepato-Biliary-Pancreatic Surgery, Hyogo College of Medicine

### Hepatologists

Namiki Izumi, Hospital Director, Musashino Red Cross Hospital

Shuichi Kaneko, Professor, Department of Gastroenterology, Graduate School of Medical, Pharmaceutical, and Health Sciences, Kanazawa University

Masatoshi Kudo, Professor, Department of Gastroenterology and Hepatology, Kinki University School of Medicine

Hiroko Iijima, Professor, Department of Hepato-Biliary-Pancreatic Surgery and Center for Ultrasound Imaging, Hyogo College of Medicine

Takuya Genda, Senior Associate Professor, Department of Gastroenterology and Hepatology, University of Juntendo Shizuoka Hospital

Ryosuke Tateishi, Senior Assistant Professor, Department of Gastroenterology, The University of Tokyo

Takuji Torimura, Professor, Division of Gastroenterology, Department of Medicine, Kurume University

### Radiologists

Hiroshi Inagaki, Chief Physician, Department of Radiology, National Cancer Center Hospital

Satoshi Kobayashi, Professor, Department of Quantum Medical Imaging, Kanazawa University Graduate School of Medical Sciences

Hideyuki Sakurai, Professor, Department of Radiation Oncology, Tsukuba University School of Medicine

Takamichi Murakami, Professor, Department of Radiology, Kobe University Graduate School of Medicine

Takeyuki Watadani, Senior Assistant Professor, Department of Radiology, University of Tokyo Hospital

#### Clinical Statistician

Yutaka Matsuyama, Professor, Department of Biostatistics and Bioinformatics,  
Graduate School of Medicine, The University of Tokyo

#### Expert Advisors

##### Surgeons

Junichi Arita, Senior Assistant Professor, Department of Hepatobiliary and Pancreatic  
Surgery, University of Tokyo Hospital

Satoru Imura, Professor, Department of Surgery, Tokushima University Hospital

Akishige Kanazawa, Department Chair, Department of Hepato-Biliary-Pancreatic  
Surgery, Osaka City General Hospital

Kazuhiko Sakamoto, Senior Assistant Professor, Department of Gastroenterological,  
Breast, and Endocrine Surgery, Yamaguchi University Graduate School of  
Medicine

Ikuo Nakamura, Assistant Professor, Department of Hepato-Biliary-Pancreatic Surgery,  
Hyogo College of Medicine

Hisashi Nakayama, Senior Assistant Professor, Division of Digestive Surgery, Nihon  
University School of Medicine

##### Hepatologists

Yoshinari Asaoka, Assistant Professor, Department of Gastroenterology, University of  
Tokyo School of Medicine

Kuniaki Arai, Assistant Professor, Department of Gastroenterology, Kanazawa  
University Hospital

Kazuomi Ueshima, Senior Assistant Professor, Department of Gastroenterology and  
Hepatology, Kinki University School of Medicine

Shunsuke Sato, Assistant Professor, Department of Gastroenterology and Hepatology,  
University of Juntendo Shizuoka Hospital

Masahito Nakano, Assistant Professor, Division of Gastroenterology, Department of  
Medicine, Kurume University

Takashi Nishimura, Senior Assistant Professor, Department of  
Hepato-Biliary-Pancreatic Surgery and Center of Ultrasound Imaging, Hyogo  
College of Medicine

Yasunori Minami, Senior Assistant Professor, Department of Gastroenterology and  
Hepatology, Kinki University School of Medicine

Yutaka Yasui, Department of Gastroenterology, Musashino Red Cross Hospital  
Tatsuya Yamashita, Senior Assistant Professor, Department of Gastroenterology,  
Kanazawa University Hospital

#### Radiologists

Masaaki Akahane, Professor, Department of Radiology, International University of  
Health and Welfare  
Toshiyuki Okumura, Professor, Department of Radiation Oncology, Tsukuba  
University School of Medicine  
Atsuya Takeda, Center Director, Radiation Oncology Center, Ofuna Chuo Hospital  
Toshihiro Furuya, Senior Assistant Professor, Department of Radiology, University of  
Tokyo Hospital  
Tetsuya Minami, Associate Professor, Department of Radiology, Kanazawa University  
Hospital

#### Working Collaborators

Tomoko Aoki, Department of Hepato-Biliary-Pancreatic Surgery and Center for  
Ultrasound Imaging, Hyogo College of Medicine  
Takahisa Eriguchi, Deputy Director, Department of Radiation Oncology, Saiseikai  
Yokohamashi Tobu Hospital  
Hiromitsu Onishi, Assistant Professor, Department of Radiology, Osaka University  
Graduate School of Medicine  
Masaki Kaibori, Associate Professor, Department of Hepato-Biliary-Pancreatic Surgery,  
Kansai Medical University Hospital  
Shigeru Kiryu, Professor, Department of Radiology, International University of Health  
and Welfare  
Hiroshi Kondo, Professor, Department of Radiology, Teikyo University School of  
Medicine  
Yozo Sato, Chief Physician, Department of Diagnostic and Interventional Radiology,  
Aichi Cancer Center Hospital  
Takuya Shimizuguchi, Department of Radiation Oncology, Tokyo Metropolitan  
Cancer and Infectious Diseases Center Komagome Hospital  
Masashi Shimohira, Senior Assistant Professor, Department of Radiology, Nagoya City  
University School of Medicine  
Nobuyuki Takemura, Director of the Hepato-Biliary-Pancreatic Surgery Division,  
Department of Surgery, Center Hospital of the National Center for Global Health

and Medicine

Masakatsu Tsurusaki, Associate Professor, Department of Radiology, Kindai University Faculty of Medicine

Ken Harada, Senior Assistant Professor, Department of Radiation Oncology, Tokai University School of Medicine

Tomoko Hyodo, Senior Assistant Professor, Department of Radiology, Kindai University Faculty of Medicine

Masakazu Hirakawa, Associate Professor, Department of Radiology, Kyushu University Beppu Hospital

Masashi Mizumoto, Senior Assistant Professor, Department of Radiation Oncology, Tsukuba University School of Medicine

Koichiro Yamakado, Professor, Department of Radiology, Hyogo College of Medicine

● External Review Panel for the Clinical Practice Guidelines for Liver Cancer

Committee Chair

Keiji Sano, Professor, Department of Surgery, Teikyo University School of Medicine

Committee Members

Hiroyuki Isayama, Senior Associate Professor, Department of Gastroenterology, University of Juntendo Hospital

Shigehiro Kokubu, Center Director, Institute for Liver Disease Minimal Invasive Treatment, Shin-Yurigaoka General Hospital

Kentaro Sakamaki, Junior Assistant Professor, Department of Biostatistics and Bioinformatics, Graduate School of Medicine, University of Tokyo

Kenichi Sugihara, Director, Daiichi Hospital and Professor Emeritus, Tokyo Medical and Dental University

Hiroki Haradome, Professor, Department of Diagnostic Radiology, Kitazato University School of Medicine

(Contributors are listed by last name in the order of the Japanese 50-character *kana* syllabary)

**Office of the Clinical Practice Guidelines for Liver Cancer**

The Japan Society of Hepatology, General Incorporated Association

Kashiwaya 2 Building 5F, 3-28-10 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan

With cooperation from the International Medical Information Center, General Incorporated Association



## **Conflicts of interest of the selected members responsible for updating the Clinical Practice Guidelines for Liver Cancer (2017 Edition)**

In accordance with the criteria shown below, the Japan Society of Hepatology (JSH) carefully scrutinized disclosures of financial relationships with companies connected with liver cancer and associated diseases provided by the Revision Committee members, expert advisors, and other contributors to the Clinical Practice Guidelines for Liver Cancer as well as their first-degree relatives. In the criteria listed under Sections A and B below, companies and corporate organizations involved in clinical studies and profit-oriented businesses are designated as companies, organizations, and groups, and the amount of money in yen indicates total sum per year.

### **A: Declarants**

1. Individuals who serve as a board member or adviser at a company, organization, or group and received compensation of 1,000,000 yen or more from the company, organization, or group.
2. Individuals who own company stock and made a profit (sum total of dividends and capital gains) of 1,000,000 yen or more or whose shares exceed 5% of the total stock the company issues.
3. Individuals who received royalties 1,000,000 yen or more from a patent owned by a company, organization, or group.
4. Individuals who received *per diem*, lecture fees, or allowances of 500,000 yen or more from a company, organization, or group for attending or presenting at meetings or providing services (time and labor) as a researcher.
5. Individuals who received 500,000 yen or more from a company, organization, or group for writing manuscripts or booklets.
6. Individuals who received research funding of 5,000,000 yen or more from a company, organization, or group for clinical research activities (eg, commissioned research, collaborative research, or proxy accounting).
7. Individuals who received a total of 1,000,000 yen or more from a company, organization, or group for clinical studies and scholarships (incentives) directly or indirectly through their department, division, or research group.
8. Individuals who belong to a department or division endowed by a company, organization, or group.
9. Individuals who received a total of 50,000 yen as gift or compensation for travel expenses not related to research, education, or medical services.

### **B: Spouses, first-degree relatives, and third parties who share income and assets with the declarants**

1. Individuals who serve as a board member or adviser at a company, organization, or group and

received compensation of 1,000,000 yen or more from the company, organization, or group.

2. Individuals who own company stock and made a profit (sum total of dividends and capital gains) of 1,000,000 yen or more or whose shares exceed 5% of the total stock the company issues.

3. Individuals who received royalties 1,000,000 yen or more from a patent owned by a company, organization, or group.

As healthcare and medical professionals or specialist physicians working in the field of liver cancer and related diseases, the committee members of the Clinical Practice Guidelines for Liver Cancer (2017 Version) compiled the guidelines to improve the level of care for target diseases, extend healthy life expectancy, and improve quality of life for patients, while ensuring the scientific and medical impartiality and validity of the content.

Listed below are the companies disclosed in the selected members' disclosures of interest (obtained between January 1, 2014, and December 31, 2016). Company names are the official names used as of July 2017. Publishers and neutral parties are not included in the list.

#### Notes

##### A: Declarants

###### 1. Compensation:

Taiho Pharmaceutical Co., Ltd.

###### 2. Profits from stock: None

###### 3. Patent royalties: None

###### 4. Lecture fees:

MSD K.K., AbbVie Inc., Otsuka Pharmaceutical Co., Ltd., Gilead Sciences, Inc., Shionogi & Co., Ltd., Taiho Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Bayer Yakuhin, Ltd., and Bristol-Myers Squibb Company.

###### 5. Manuscript fees: None

###### 6. Research grants and subsidies:

MSD K.K., AbbVie Inc., Eisai Co., Ltd., Ono Pharmaceutical Co., Ltd., Tsumura & Co., Yakult Honsha Co., Ltd., KUBIX Inc., Kyowa Hakko Kirin Co., Ltd., Kowa Company, Ltd., Taiho Pharmaceutical Co., Ltd., Toyo Kohan Co., Ltd., NEC Corporation, PHC Holdings Corporation/Panasonic Medical Solutions Co., Ltd., and Bristol-Myers Squibb Company.

###### 7. Scholarships (incentives):

CSL Behring, MSD K.K., Astellas Pharma Inc., AstraZeneca K.K., AbbVie Inc., Abbott Japan Co., Ltd., Abbott Vascular Japan K.K., Eisai Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Kataoka Co., Ltd., Yakult Honsha Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Gilead Sciences, Inc., Covidien Japan, Sanofi K.K., Shionogi & Co., Ltd., Zeria Pharmaceutical Co., Ltd., Daiichi Sankyo Company, Limited, Taisho Toyama Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, Mitsubishi Tanabe Pharma Corporation, Chugai Pharmaceutical Co., Ltd., Teijin Pharma Limited, Terumo Corporation, Torii Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Japan Blood Products Organization, Boehringer Ingelheim Japan,

Inc., Nihon Medi-Physics Co., Ltd., Novartis Pharma K.K., Novo Nordisk Pharma Ltd., Bayer Yakuhin, Ltd., Handa Co., Ltd., Pfizer Japan Inc., Fuji Pharma Co. Ltd., Fujifilm RI Pharma Co., Ltd., Bristol-Myers Squibb Company, and Mylan EPD, Ltd.

8. Endowments from companies, organizations, and groups: None

9. Receipt of travel expenses, gifts, etc.: None

**B: Spouses, first-degree relatives, and third parties who share income and assets with the declarants**

1. Compensations: None

2. Profits from stock: None

3. Patent royalties: None